Traders Purchase Large Volume of Put Options on Achillion Pharmaceuticals (ACHN)
Shares of Achillion Pharmaceuticals (NASDAQ:ACHN) was the target of some unusual options trading on Thursday. Traders acquired 5,096 put options on the company, Analyst Ratings Network reports. This represents an increase of approximately 147% compared to the average volume of 2,063 put options.
In other Achillion Pharmaceuticals news, Insider Ra Capital Management, Llc acquired 2,800,000 shares of Achillion Pharmaceuticals stock in a transaction dated Monday, September 30th. The shares were purchased at an average price of $2.98 per share, for a total transaction of $8,344,000.00. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.
A number of analysts have recently weighed in on ACHN shares. Analysts at Deutsche Bank downgraded shares of Achillion Pharmaceuticals from a “buy” rating to a “hold” rating in a research note to investors on Monday, September 30th. Separately, analysts at Wells Fargo & Co. downgraded shares of Achillion Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note to investors on Monday, September 30th. Finally, analysts at Piper Jaffray Cos. downgraded shares of Achillion Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research note to investors on Monday, September 30th. They now have a $5.00 price target on the stock, down previously from $15.00. One research analyst has rated the stock with a sell rating and ten have issued a hold rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $6.07.
Shares of Achillion Pharmaceuticals (NASDAQ:ACHN) traded up 1.44% during mid-day trading on Thursday, hitting $2.47. 2,932,230 shares of the company’s stock traded hands. Achillion Pharmaceuticals has a 52-week low of $2.40 and a 52-week high of $11.36. The stock’s 50-day moving average is $6.0 and its 200-day moving average is $7.06. The company’s market cap is $238.7 million.
Achillion Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.